Calastone Announces Strategic Partnership With Microsoft to Accelerate the Digital Transformation of Funds and Collective Investments
1.12.2021 11:00:00 EET | Business Wire | Press release
Calastone, the largest global funds network, has signed a partnership agreement with Microsoft, which will see the firms collaborate on the use of cloud and distributed ledger technology to create market efficiency across the global investment funds industry. By combining Calastone’s network, technology and market experience, with Microsoft’s expertise and track record in delivering capital markets solutions in Microsoft Azure, the companies will drive new opportunities for collective investments worldwide.
Calastone is leveraging its network as the foundation on which to enable the asset management industry to realise its digital transformation agenda. As investor requirements grow for accessible, low cost and innovative ways of investing, Calastone is applying the very latest technologies to build the next generation infrastructure for the distribution of investment funds.
Calastone introduced DMI Fund Services, a suite of solutions that provides fund managers, administrators and distributors a fully digital operating model, enabled through the use of cloud and DLT. In the development of DMI Fund Services, Calastone chose Azure for its reliability, security, scalability and leading-edge confidential computing platform which includes the confidential consortium framework (CCF).
CCF is an open-source framework for building a new category of secure, highly available, and performant applications that focus on multi-party confidential compute and storage. Through Calastone’s practical experience having operated DLT since 2019, the firm has selected CCF as the best framework to provide the rapid scalability and security required to operate on a global scale. This will allow for transformative fund trading and dynamic data sharing across the entire industry, in one common infrastructure.
As DMI Fund Services and Azure confidential computing evolve, the partnership between Calastone and Microsoft will deliver new capabilities, which will enable transfer agents, fund managers and fund distributors to transform how they operate and service their clients, and ultimately gain from the wholescale market efficiency to lower the overall cost of investing.
Adam Belding, Chief Technology Officer at Calastone, said, “The funds industry is at a turning point, with the need to innovate and digitally transform becoming the key goal of asset managers and asset servicers. We absolutely believe that this technology is the future for the funds industry, and for financial services generally. We have great ambitions for DMI Fund Services and our wider product set, and so we looked to Microsoft, one of the world’s leading technology companies, with a proven expertise in enabling distributed ledger and cloud solutions for the financial services sector, to help us drive towards these goals.
“Microsoft’s technologies and industry track record will enable the rapid scaling we see for DMI Fund Services, and our global funds network generally. We are excited to share this vision with Microsoft and look forward to collaborating to revolutionize the funds sector and provide a more efficient and friction-free experience for all.”
Bill Borden, Corporate Vice President of Worldwide Financial Services at Microsoft, said, “We’re excited to work with Calastone to enable innovation in the asset management and capital markets industries. Calastone’s DMI Fund Services, combined with Microsoft Azure and distributed ledger technology, unlocks a secure and scalable way for firms to access the critical data and insights they need to further enhance the client experience, significantly reduce operating costs, and develop new investment models.”
About Calastone
Calastone is the largest global funds network, connecting the world’s leading financial organisations.
Our mission is to help the funds industry transform by creating innovative new ways to automate and digitalise the global investment funds marketplace, reducing frictional costs and lowering operational risk to the benefit of all. Through this, we generate the opportunity for the industry to deliver greater value back to the end investor.
Over 2,800 clients in 51 countries and territories benefit from Calastone’s services, processing £200 billion of investment value each month.
Calastone is headquartered in London and has offices in Luxembourg, Hong Kong, Taipei, Singapore, New York, Milan and Sydney.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211201005388/en/
Contact information
FTI Consulting LLP
Ollie Bailey-Pratt / Darius Alexander
calastone@fticonsulting.com
Tel: 020 3727 1000
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 12:47:00 EEST | Press release
Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food products. Within this inspiring premise, Good Food Makers confirms itself as one of the main levers f
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 11:16:00 EEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
